Periodontal surgery using rhFGF‐2 with deproteinized bovine bone mineral or rhFGF‐2 alone: 2‐year follow‐up of a randomized controlled trial

Abstract

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Healing of Experimental Periodontal Defects Following Treatment with Fibroblast Growth Factor-2 and Deproteinized Bovine Bone Mineral

“…It is of interest to note that, in comparison between the FGF-2 + DBBM and FGF-2 alone groups, no significant difference was found in the micro-CT and histological results. This finding was in line with our clinical observations [12,21].…”

“…Combined use of signaling molecules and bone substitutes is clinically recommended for the treatment of deep noncontained intrabony defects [56,57]. In our recent clinical study [21], the treatment of intrabony defects with FGF-2 + DBBM yielded significantly greater RBF when compared with FGF-2 alone at 2 years postoperatively, in cases of 1-2-wall defects. This presented the possibility that such combination therapy may be clinically beneficial in certain bone defect configurations.…”

Comparison of periodontal wound healing/regeneration by recombinant human fibroblast growth factor‐2 combined with β‐tricalcium phosphate, carbonate apatite, or deproteinized bovine bone mineral in a canine one‐wall intra‐bony defect model

“…These findings were similar to those of previous animal studies evaluating periodontal wound healing/regeneration following rhFGF‐2/DBBM application (Sakata et al, 2006; Murakami et al, 2021). Additionally, a recent report indicated that the treatment of intra‐bony defects with rhFGF‐2/DBBM yielded significantly greater radiographic bone fill compared with rhFGF‐2 alone, particularly in one‐ and two‐wall defects (Aoki et al, 2021). These positive results may be explained by in vitro data demonstrating that rhFGF‐2 promotes cell viability, proliferation, angiogenesis, and osteogenic differentiation on DBBM (Murakami et al, 2021).…”

“…Fibroblast growth factor‐2 (FGF‐2), a member of the heparin‐binding growth factor family, is involved in broad mitogenic and cell survival activities, including angiogenesis, wound healing, and embryonic development. Topical application of recombinant human FGF‐2 (rhFGF‐2) was found to support periodontal regeneration without ankylosis or epithelial down‐growth in periodontal intra‐bony defects in several animal studies (Anzai et al, 2010; Shirakata et al, 2010, 2013; Murakami et al, 2021) and promoted CAL gain and alveolar bone gain in humans (Kitamura et al, 2011, 2016; Aoki et al, 2021). Moreover, new bone formation was found to be more extensive in rhFGF‐2‐treated sites compared with enamel matrix derivative‐treated sites in human/animal intra‐bony defects (Shirakata et al, 2010; Ninomiya et al, 2013; Kitamura et al, 2016).…”

“…However, the fluid consistency of the current rhFGF‐2 product may not allow sufficient space making, which may lead to the collapse of the flap and subsequently limit the outcomes of regenerative surgery in non‐contained defects, as indicated by other bioactive agents/biomaterials (Lekovic et al, 2000; Sakata et al, 2006). At present, however, it is unknown which combination of rhFGF‐2 and various bone substitutes is desirable for obtaining predictable periodontal wound regeneration in non‐contained defects (Cochran et al, 2016; Aoki et al, 2021). Therefore, the aim of the present study was to histologically compare periodontal wound healing/regeneration of one‐wall intra‐bony defects treated with rhFGF‐2 and β‐TCP, CO 3 Ap, or DBBM in dogs.…”